In this fifth Catenion webinar, consultants Dr. Ana Rita da Costa and Dr. Ilkin Ozer analyze female health: the branch of medicine that treats and diagnoses conditions affecting females’ physical and emotional well-being, including female-specific conditions and general conditions that affect females differently or disproportionately. The analysis leaves out female cancers and focuses on companies developing drugs for female health conditions, with a short look at femtech. (In the webinar, “females” refers to people with uteri, who may or may not identify as women.)
Topics covered:
- History of innovation and policy: from the late 1970s, females of childbearing potential were excluded from clinical trials after thalidomide. The FDA rescinded the guideline in 1993, yet in 2001 two-thirds of clinical trials still excluded females, and the NIH only introduced its policy on sex as a biological variable in 2016.
- Sex differences and safety: females experience adverse reactions nearly twice as often as males. A 2020 study found a dose gender gap for 86 FDA-approved medications, and several drugs and devices were withdrawn after adverse events in females (examples include DES, Pondimin, Essure and transvaginal mesh).
- Marketed drugs and unmet needs: the main drug classes (anti-infectives, painkillers and NSAIDs, hormone replacement therapy and contraceptives) have seen little innovation, and more than two-thirds of marketed female health drugs are off patent. Unmet needs remain high: one in four females of reproductive age experience menstrual disorders, and 1.2 billion females will be in menopause by 2030.
- Barriers to innovation: male physiology as the default in modern medicine, socioeconomic inequality, stigma, low political priority, and the under-representation of women in venture capital, funding agencies and pharma leadership. Only around 4% of US healthcare R&D spending goes directly to female health, and only 1% to areas outside oncology.
- Players and pipeline: most marketed drugs target infertility and anovulation, while endometriosis stands out as the top indication in active pipelines. Big pharma collaborates with smaller companies, for example Bayer’s acquisition of KaNDy and the collaboration between Myovant and Pfizer on relugolix. Sales of female health therapies (excluding cancer) are forecast to grow from 9 billion dollars in 2021 to 14 billion in 2028, with menopause growing fastest.
- Why invest: females are half of the world’s population, live longer, carry a growing burden of chronic disease and make most health care decisions for their families. Funding rose strongly after 2020, and femtech venture investment reached over 2.4 billion dollars in 2021, although femtech still receives only 5% of digital health funding.
Conclusion: Catenion considers female health an underexploited market with great potential for innovation and socioeconomic returns. It recommends sex-specific academic research, more research grants, systematic scouting by investors, novel mechanisms of action instead of generics, and trial designs that treat sex as a fundamental variable.



